EP2701536A1 - Essbarer braunalgenextrakt mit niedrigem jodgehalt - Google Patents

Essbarer braunalgenextrakt mit niedrigem jodgehalt

Info

Publication number
EP2701536A1
EP2701536A1 EP12724684.1A EP12724684A EP2701536A1 EP 2701536 A1 EP2701536 A1 EP 2701536A1 EP 12724684 A EP12724684 A EP 12724684A EP 2701536 A1 EP2701536 A1 EP 2701536A1
Authority
EP
European Patent Office
Prior art keywords
extract
algae
algae extract
polyphenols
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12724684.1A
Other languages
English (en)
French (fr)
Inventor
Guy POTIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Algues et Mer SAS
Original Assignee
Algues et Mer SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algues et Mer SAS filed Critical Algues et Mer SAS
Publication of EP2701536A1 publication Critical patent/EP2701536A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
    • A23L17/60—Edible seaweed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction

Definitions

  • the present invention generally relates to an extract of brown algae, especially food and its preparation process, this extract having a very low iodine content, a high content of polyphenols (or polyphenol compounds) and high levels of alginates, polysaccharides and minerals.
  • the present invention also relates to an oral absorption composition comprising such an extract.
  • the enriched human being seeks, whatever his culture, greater comfort (in the sense of a physically less demanding life) and a more varied and richer diet (especially increased consumption of meat or more sophisticated manufactured products).
  • the conjunction of these two phenomena favors the development of a set of risk factors affecting his health.
  • the human being decreases his energy consumption, but by feeding in a profusion and in a richer way, he consumes much more than his nutritional needs. This results in the appearance of a syndrome, which is described as metabolic.
  • metabolic syndrome in the sense of the present invention a set of metabolic disturbances, which although not falling within the strict definition of the disease, strongly predisposes the development and progression of true chronic diseases such as hypertension , arteriosclerosis, or diabetes.
  • a pre-diabetic is six times more likely to develop diabetes than a normal individual.
  • medical care does not occur more often than when the disease is declared.
  • Hygiene and dietary rules are then in place (more balanced meals and maintenance of physical activity) but are insufficient at this stage of the disease, which makes it necessary to use drugs (eg cholesterol-lowering drugs, antidiabetic drugs. ..).
  • Certain food products have been specifically developed to limit the development of these pathologies. These include products based on polyunsaturated fatty acids or fat adsorbers, but which are not always of real interest in the long term. Indeed, the endogenous component of these pathologies is preponderant (it is estimated at 20% the influence of dietary intakes on hypercholesterolemia).
  • the present invention therefore relates to the manufacture of food products (extracts and oral absorption compositions comprising these extracts) for the management of individuals with metabolic syndrome, and in particular pre-diabetics.
  • oral absorption composition means a product obtained by transformation of a food which is ingested in addition to the diet, around the meals, this product having only one strictly digestive action (no absorption is necessary for the digestive activity of the product and the action is done in the food bowl).
  • brown algae food extracts One known solution for the sustainable and effective management of individuals with metabolic syndrome or pre-diabetic individuals is the use of brown algae food extracts. Indeed, the inhibitory power of brown algae extracts, known to be rich in phlorotannins, on certain enzymes present in the digestive system has already been demonstrated in several publications [1] to [3] and few other food plants have such activity. These enzymes degrade complex nutrients into assimilable nutrients (especially sugars) and are therefore one of the important players influencing postprandial blood levels. By inhibiting the activity of these enzymes, the nutrients in the food bolus are more slowly digested and absorbed when taking a meal. The glycemic, insulinemic and triglyceric responses are diminished.
  • the brown algae extracts help to reduce the negative impact of excessive food intake compared to the needs, while providing certain elements necessary for the organism such as:
  • alginates which form a calcium gel in the stomach, contributing to the enzymatic inhibition activity of polyphenols (congestion of the nutrient attack sites by the enzymes) and causing a satiety effect [5];
  • fucans which inhibit the binding of Helicobacter pilori digestive walls limiting the risk of ulcers [6] or that limit enzymatic hydrolysis of starch by inhibitory effects [7].
  • the known brown algae extracts are certainly rich in phlorotannins, and thus have an inhibitory activity on certain enzymes of the digestive system.
  • they have a high iodine content, even when the extracts are subjected to deiodization. Indeed, during this desiodization, the iodine is only partially eliminated, and the residual content (300 ppm for the less rich) limits the maximum daily usable dose (500mg), and thus the clinical interest of the product.
  • the extract marketed by the applicant company itself under the brand InSea 2 ® which is a brown seaweed extract acting as an inhibitor of carbohydrate digestive enzymes, the DC-amylase and cc-glucosidase
  • the brown seaweed extract marketed by the company under the brand Bioserae Id-AIG TM the brown seaweed extract marketed by the company under the brand Bioserae Id-AIG TM
  • the white kidney bean extract marketed by Ingredia Nutritional branded Phase 2 ® or the brown algae extract manufactured by the company Diana Naturals and subject of the French patent application FR2914190.
  • the latter product is intended to combat inflammation, arthritis and allergies, it departs from the scope of the present invention.
  • Acarbose DCI (marketed by BAYER under the tradename Glucor® ND) and Orlistat DCI (marketed by the ROCHE and Glaxo SmithKline laboratories under the trade names Xenical® ND and Alli TM ND, respectively).
  • the active pharmaceutical ingredient Acarbose DCI has the disadvantage of causing flatulence, and therefore the nonobservance of the treatment
  • the pharmaceutical active ingredient Orlistat DCI presents the disadvantage of blocking the absorption of lipids, and thus to cause a very strong acceleration of the transit, and thus finally the nonobservance of the treatment.
  • the alginates are necessarily eliminated, whether by acidification (manufacture of the InSea 2 ® product), or by precipitation with calcium chloride, for example (process described in FR2914190), these additional steps entail not only the elimination of alginates (biological interest) but also additional costs;
  • iodine removal is by diafiltration (FR2914190): some of the iodine is entrained in the permeate, but also some of the minerals and dry matter; the more one wants to eliminate the iodine, the more it is necessary to diafilter, and the more the extract will be poor in molecules whose molecular mass is lower than the threshold of cutoff (InSea 2 ®: tangential ultrafiltration). In addition, certain contaminants present in the native extract and whose molecular mass is greater than the cut-off point of the membrane will concentrate in the retentate;
  • the purpose of the present invention is therefore the development of a brown algae extract with a reduced iodine content, but retaining the initial level of minerals, alginates, fucans and phlorotannins (polyphenols), such as to be as close as possible to the native extract.
  • the subject of the present invention is an algae extract, characterized in that it comprises less than 50 ppm of iodine and between 5 and 15%, and preferably between 8 and 10% of polyphenols, said percentage of polyphenols being expressed in chlorogenic acid equivalent relative to the dry weight of the extract.
  • polyphenols means the phlorotannins (or phenolic antioxidants) generally present in brown algae: these are chemical structures found very largely in the terrestrial plants and algae.
  • the special feature of algae polyphenols is that they are very large molecules whose major monomer is phloroglucinol (hence the name phlorotannins).
  • the algae extract according to the invention has an inhibitory activity on -amylase, -glucosidase and lipase.
  • the reduced iodine content of the algae extract according to the invention allows a daily intake of up to 3 g of extract according to the invention, thus conforming to the daily iodine intake recommended by the European Union. in Regulation 2006/352 fixing the maximum daily quantity of iodine at 150 mg / day (see also the corresponding French regulation as published in JORF 123 of 9 May 2006).
  • the algae extract according to the invention can advantageously be obtained from brown algae, preferably food.
  • the algae extract according to the invention may advantageously be obtained from algae (which may in particular be microalgae or macroalgae) belonging to at least one of the species selected from the species Ascophyllum sp. , Fucus sp. , Himanthalia sp. , Undaria sp. , and Laminaria sp ..
  • algae of the species Ascophyllum nodosum are preferably used.
  • the algae extract according to the invention may contain between 5 and 9% of alginates, percentage expressed as glucuronic acid equivalent relative to the dry weight of the extract.
  • alginates in the algae extract according to the invention allows the formation of a calcium gel which contributes to the enzymatic inhibition of phlorotannins and causes an effect of satiety.
  • alginates also commonly used in the treatment of gastroesophageal reflux esophageal ⁇ , would, through their power chelator, detoxify the body.
  • the algae extract according to the invention may also advantageously contain the majority of minerals (except iodine) contained in said algae before their transformation, and more particularly calcium, magnesium, potassium and phosphorus.
  • the presence of these minerals is essential to the proper functioning of the body of the human being (multiple actions).
  • the algae extract according to the invention may also advantageously comprise fucans, the properties of which are numerous and affect many areas (prevention of gastric ulcers, relief of stomach disorders, etc.). Fucans in particular exhibit inhibitory effects on the enzymatic hydrolysis of starch.
  • the present invention also relates to an oral absorption composition comprising an extract of algae according to the invention.
  • the oral absorption composition according to the invention is vehicle-free, the algae extract being incorporated into said composition without any addition.
  • the oral absorption composition according to the invention, it comprises an orally acceptable carrier present in said composition in a proportion of 0.5 by weight relative to the total weight of said composition.
  • compositions according to the invention may be in any ingestible oral dosage form, and especially in the form of capsules, lozenges, tablets, ampoules, capsules, herbal teas, oral solutions or suspensions, and powders. , flakes or granules.
  • the present invention further relates to a process for preparing an algae extract according to the invention, which comprises the following steps:
  • said method being characterized in that it comprises between the step of purifying the liquid phase and the step of drying said aqueous extract, a specific deiodification step of said purified aqueous extract which is carried out by passing on a resin exchange resin. ions.
  • the process according to the invention makes it possible, without using an organic solvent, to eliminate colloids such as alginates, obtaining a brown algae extract with a decrease in the iodine content (equal to or less than 50 ppm) which is more important than with a method of the prior art, while having a standardized polyphenol content.
  • the extract thus obtained is closer to the native extract (no loss of alginates and fucans, no loss of inhibitory activity, little loss of minerals essential substances such as calcium, potassium, magnesium and phosphorus).
  • the drying step may advantageously be carried out by atomization, lyophilization, vacuum oven or fluidized bed.
  • the drying is carried out by atomization.
  • the drying step is preceded by a step of concentration and / or standardization of said aqueous extract by adding soluble dietary fiber (in particular wheat, corn, etc.). to obtain a polyphenol content of between 5 and 15% and preferably between 8 and 10%.
  • soluble dietary fiber in particular wheat, corn, etc.
  • standardization means a step intended to adjust the polyphenol content in the extract whatever the nature or origin of the algae used to obtain the extract.
  • soluble dietary fibers examples include the soluble dietary fibers marketed by Roquette under the trademark Nutriose®.
  • the subject of the present invention is also the use of the composition according to the invention for the management of weight, the management of the metabolic syndrome, the glycemic regulation (prediabetes), the limitation of overweight, the lipidemic regulation (cholesterolemia high or subnormal), minor dyspeptic disorders, digestive acidity or mineral supplementation in humans or animals.
  • the disease is not yet declared.
  • the present invention also relates to an oral absorption composition comprising an algae extract according to the invention for its use as a medicament.
  • composition according to the invention can be used as a medicament in the treatment of diabetes, hypercholesterolemia, arterial hypertension, stroke, cardiovascular diseases, obesity, dyspepsia (digestive disorders), gastroesophageal reflux disease (GERD), gastric ulcers and mineral deficiencies in humans or animals.
  • diabetes hypercholesterolemia
  • arterial hypertension stroke
  • cardiovascular diseases obesity
  • dyspepsia digestive disorders
  • gastroesophageal reflux disease GABA
  • gastric ulcers gastric ulcers and mineral deficiencies in humans or animals.
  • Example 1 Preparation of a brown algae extract according to the present invention.
  • Fresh or dried brown seaweed Ascophyllum nodosum is harvested and then crushed.
  • An aqueous maceration is then carried out, the main objective of which is to extract the main constituents of the alga, namely polyphenols, fucans, alginates and minerals.
  • the extraction temperature is between 40 ° C and 95 ° C, and the extraction time is at least six hours.
  • a solid-liquid separation is carried out on a vibrating screen or centrifugal separator.
  • the aqueous extract thus obtained is then clarified so as to eliminate a maximum of microparticles in suspension and thus prevent clogging of the resin in the next step, this operation being carried out on filter press, filter plate or centrifugal decanter.
  • An iodine removal step of the extract is then carried out to reach a final content of less than 50 ppm. Removal of iodine from the aqueous extract is by passage over an ion exchange resin at room temperature (between 15 ° C and 25 ° C).
  • the extract is then concentrated under vacuum at low temperature to reach between 10 and 15% of dry matter, then it is standardized by adding soluble dietary fiber to obtain a final content of polyphenols between 8 and 10%.
  • the extracted liquid thus obtained is then spray-dried to obtain a fine brown powder rich in polyphenols.
  • Example 2 Determination of iodine, polyphenols, fucans and alginates of the extract of Example 1
  • this assay is performed by sodium thiosulfate titrimetry (ppm) according to the Codex Method of Nutrition and Dietary Foods, ESPA / CN 109/84.
  • this assay is carried out according to the FOLIN method and a content expressed in chlorogenic acid is obtained.
  • this assay is carried out according to the method of BLUMENKRANTZ and GA-HANSEN to metahydroxydiphenyl and a content expressed as glucuronic acid is obtained.
  • dosage is performed according to the DUBOIS method, the principle of which consists in determining the glucose content.
  • alginate content 5 to 9%, based on the dry matter
  • total sugar content about 30%;
  • the extract obtained in Example 1 has the following characteristics:
  • starch is incubated with an enzyme (human salivary amylase for example). This incubation leads to the digestion of starch and the production of maltose; a colored product is added and is intended to stop the enzymatic reaction and to reveal the presence of maltose;
  • an enzyme human salivary amylase for example
  • a colorimetric assay makes it possible to quantify, at a precise wavelength, the residual maltose; the addition of an "inhibitor" to the solution before incubation leads to the reduction of maltose and thus of its colorimetric dosage.
  • control solution makes it possible to calculate a percentage of inhibition.
  • Table 1 of results shows that at the level of the inhibition of digestive enzymes, the in vitro results obtained for the extracts of algae according to the invention (whatever the batch from which it is derived) are equivalent to those obtained with the algae extract of the prior art InSea 2 ® and the pharmaceutical active Glucor® ND.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
EP12724684.1A 2011-04-27 2012-04-23 Essbarer braunalgenextrakt mit niedrigem jodgehalt Withdrawn EP2701536A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1153581A FR2974479B1 (fr) 2011-04-27 2011-04-27 Extrait d'algues brunes alimentaires a faible teneur en iode
PCT/FR2012/050887 WO2012146863A1 (fr) 2011-04-27 2012-04-23 Extrait d'algues brunes alimentaires à faible teneur en iode

Publications (1)

Publication Number Publication Date
EP2701536A1 true EP2701536A1 (de) 2014-03-05

Family

ID=44533245

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12724684.1A Withdrawn EP2701536A1 (de) 2011-04-27 2012-04-23 Essbarer braunalgenextrakt mit niedrigem jodgehalt

Country Status (4)

Country Link
US (1) US20140199410A1 (de)
EP (1) EP2701536A1 (de)
FR (1) FR2974479B1 (de)
WO (1) WO2012146863A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106290686B (zh) * 2016-09-14 2018-08-10 广州王老吉药业股份有限公司 Hplc-ms-ms测定王老吉凉茶成分含量的方法
WO2019211442A1 (en) * 2018-05-04 2019-11-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fucoidans from diatoms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624567A (en) 1996-02-12 1997-04-29 Umpqua Research Company Process for removing iodine/iodide from aqueous solutions
CA2547381A1 (en) * 2003-12-10 2005-06-23 Riken Vitamin Co., Ltd. Marine algae extract and glycosidase inhibitor containing the same
CA2548899A1 (en) * 2003-12-10 2005-06-23 Riken Vitamin Co., Ltd. Marine algae extract and lipase inhibitor containing the same
WO2006017943A1 (en) * 2004-08-17 2006-02-23 Ocean Nutrition Canada Ltd. Ascophyllum compositions and methods
EP1977756A1 (de) 2007-03-28 2008-10-08 Diana Naturals Algenextrakt mit Polyphenolen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697409B1 (fr) * 1992-11-03 1995-01-20 Nature Algues Procédé d'élimination sélective de l'iode dans les algues brunes et extrait d'algues ainsi obtenu.
JP3425412B2 (ja) * 2000-07-03 2003-07-14 株式会社シマヤ 清涼飲料の製造方法
CN100425526C (zh) * 2005-08-18 2008-10-15 山东寻山水产集团有限公司 一种从海带中提取碘的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624567A (en) 1996-02-12 1997-04-29 Umpqua Research Company Process for removing iodine/iodide from aqueous solutions
CA2547381A1 (en) * 2003-12-10 2005-06-23 Riken Vitamin Co., Ltd. Marine algae extract and glycosidase inhibitor containing the same
CA2548899A1 (en) * 2003-12-10 2005-06-23 Riken Vitamin Co., Ltd. Marine algae extract and lipase inhibitor containing the same
WO2006017943A1 (en) * 2004-08-17 2006-02-23 Ocean Nutrition Canada Ltd. Ascophyllum compositions and methods
EP1977756A1 (de) 2007-03-28 2008-10-08 Diana Naturals Algenextrakt mit Polyphenolen

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
ALGAE ACTIVE INGREDIENTS, IMPAG NEWS, vol. 12, October 2002 (2002-10-01), pages 2+ *
BARWELL C.J. ET AL: "ISOLATION AND CHARACTERIZATION OF BROWN ALGAL POLYPHENOLS AS INHIBITORS OF ALFA-AMILASE, LIPASE AND TRYSIN", JOURNAL OF APPLIED PHYCOLOGY, vol. 1, no. 4, December 1989 (1989-12-01), pages 319 - 323, XP003035578
BURTIN P.: "NUTRITIONAL VALUE OF SEAWEEDS", ELECTRON. J. ENVIRON. AGRIC. FOOD CHEM., vol. 2, no. 4, 2003, XP055192525, Retrieved from the Internet <URL:HTTP://OLD.ANALYTICAL.CHEM.ITB.AC.ID/COURSESDATA/16/MODDATA/ASSIGNMENT/15/576/JURNAL_BIOPANG7.PDF>
BURTIN: "nutritional value of seaweeds", ELECTRIC JOURNAL OF ENVIRONMENTAL, AGRICULTURAL AND FOOD CHEMISTRY, vol. 2, no. 4, 2003 *
COSMETICS: "ALGAE ACTIVE INGREDIENTS", IMPAG NEWS: COSMETIC, no. 12, October 2002 (2002-10-01), pages 1 - 8, XP003035577
GÓMEZ-JACINTO V. ET AL: "IODINE SPECIATION IN IODINE-ENRICHED MICROALGAE CHLORELLA VULGARIS", PURE APPL. CHEM, vol. 82, no. 2, 31 January 2010 (2010-01-31), pages 473 - 481, XP055192604, DOI: 10.1351/PAC-CON-09-08-01
KAMMERER J. ET AL: "ENRICHMENT AND FRACTIONATION OF MAJOR APPLE FLANOVOIDS, PHENOLIC ACIDS DIHYDROCHALCONES USING ANION EXCHANGE RESINS", vol. 44, no. 4, May 2011 (2011-05-01), pages 1079 - 1087, XP055192550, DOI: 10.1016/J.LWT.2010.10.008
KLLOAREG B. ET AL: "POLYANIONIC CHARACTERISTICS OF PURIFIED SULPHATED HOMOFUCANS FROM BROWN ALGAE", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 8, no. 6, 1986, pages 380 - 386, XP025215867, DOI: 10.1016/0141-8130(86)90060-7
LAMELA ET AL, JOURNAL OF ETHNOPHARMACOLOGY, vol. 27, 1989, pages 35 - 43 *
LAMELA M. ET AL: "HYPOGLYCEMIC ACTIVITY OP SEVERAL SEAWEED EXTRACTS", JOURNAL OF ETHNOPHARMACOLOGY, vol. 27, no. 1-2, November 1989 (1989-11-01), pages 35 - 43, XP025499174, DOI: 10.1016/0378-8741(89)90075-5
OCK KYOUNG CHUN: "CONSIDERATION ON EQUIVALENT CHEMICALS IN TOTAL PHENOLIC ASSAY OF CHLOROGENIC ACID-RICH PLUMS", FOOD RESEARCH INTERNATIONAL, vol. 37, no. 4, May 2004 (2004-05-01), pages 337 - 342, XP055192609, DOI: 10.1016/J.FOODRES.2004.02.001
OHTA ET AL., BIOSCI. BIOTECHNOL. BIOCHEM., vol. 66, no. 7, 2002, pages 1552 - 1554 *
OHTA T. ET AL: "ALPHA-GLUCOSIDASE INHIBITORY ACTIVITY OF A 70% METHANOL EXTRACT FROM EZOISHIGE (PELVETIA BABINGTONII DE TONI) AND ITS EFFECT ON THE ELEVATION OF BLOOD GLUCOSE LEVEL IN RATS.", BIOSCI BIOTECHNOL BIOCHEM, vol. 66, no. 7, July 2002 (2002-07-01), pages 1552 - 1554, XP055192543, DOI: 10.1271/BBB.66.1552
See also references of WO2012146863A1
SHAH M. ET AL: "IODINE SPECIATION STUDIES IN COMMERCIALLY AVAILABLE SEAWEED BY COUPLING DIFFERENTCHROMATOGRAPHIC TECHNIQUES WITH UV AND ICP-MS DETECTION", JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, vol. 20, no. 3, February 2005 (2005-02-01), pages 176 - 182, XP055192547, DOI: 10.1039/B415756G
TEAS ET AL, THYROID, vol. 14, no. 10, 2004, pages 836 - 841 *
TEAS J.: "VARIABILITY OF IODINE CONTENT IN COMMON COMMERCIALLY AVAILABLE EDIBLE SEAWEEDS", THYROID, vol. 4, no. 10, October 2004 (2004-10-01), pages 836 - 841, XP055192539, DOI: 10.1089/THY.2004.14.836
TRUUS K.: "ALGAL BIOMASS FROM FUCUS VESICULOSUS (PHAEOPHYTA): INVESTIGATION OF THE MINERALAND ALGINATE COMPONENTS", PROC. ESTONIAN ACAD. SCI. CHEM., vol. 50, no. 2, 2001, pages 95 - 103, XP055192528, Retrieved from the Internet <URL:HTTP://WWW.KIRJ.EE/PUBLIC/VA_KE/K50-2-4.PDF>
WANG ET AL, FOOD CHEMISTRY, vol. 116, 2009, pages 240 - 248 *
WANG K.E. ET AL: "DETERMINATION OF IODINE AND BROMINE COMPOUNDS BY ION CHROMATOGRAPHY/DYNAMIC REACTION CELL INDUCTIVELY COUPLED PLASMA MASS SPECTROMETRY", ANALYTICAL SCIENCES, vol. 24, no. 4, April 2008 (2008-04-01), pages 509 - 514, XP055192549
WANG T. ET AL: "TOTAL PHENOLIC COMPOUNDS, RADICAL SCAVENGING AND METAL CHELATION OF EXTRACTS FROMICELANDIC SEAWEEDS", FOOD CHEMISTRY, vol. 116, no. 1, 25 February 2009 (2009-02-25), pages 240 - 248, XP026053928, DOI: 10.1016/J.FOODCHEM.2009.02.041

Also Published As

Publication number Publication date
FR2974479A1 (fr) 2012-11-02
WO2012146863A1 (fr) 2012-11-01
FR2974479B1 (fr) 2014-01-10
US20140199410A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
Sumiyoshi et al. Low molecular weight chitosan inhibits obesity induced by feeding a high‐fat diet long‐term in mice
EP2285390B1 (de) Verfahren zur Gewinnung eines Extrakts aus Preiselbeertresten zur Prävention und Behandlung von Erkrankungen wie Karies, Zahnfleischentzündung oder Halsentzündung
JP2010209051A (ja) 脂肪吸収抑制剤
FR3013222A1 (fr) Extrait d&#39;algues pour son utilisation en tant qu&#39;agent immunomodulateur
WO2002082930A1 (fr) Preparation a base de cactaceae ayant la propriete de fixer les graisses, et procede d&#39;obtention d&#39;une telle preparation
EP2701536A1 (de) Essbarer braunalgenextrakt mit niedrigem jodgehalt
EP3650035B1 (de) Rotalgenextrakt für den einsatz zur vorbeugung und behandlung von darmbeschwerden
WO2011070970A1 (ja) 胸腺間質性リンパ球新生因子過剰発現抑制剤
EP2010200B1 (de) Anwendung von polysacchariden aus fungi als pharmazeutischen zusammensetzung oder als nahrungsmittelergänzung
KR101478196B1 (ko) 꾸지뽕을 주성분으로 하는 항산화 및 당뇨병 예방용 조성물
WO2010116866A1 (ja) メタボリックシンドローム改善又は予防剤
US20100173025A1 (en) Fat absorption inhibitory composition
JP2008214246A (ja) Ａｇｅ生成阻害剤およびその製造方法
FR3017536A1 (fr) Compositions pour la prevention et/ou le traitement de pathologies liees a l&#39;alpha-glucosidase
JP2001299272A (ja) リパーゼ阻害剤
WO2024121525A1 (fr) Extrait d&#39;algue du genre ulva pour le traitement de troubles induits par un syndrome metabolique
FR2836337A1 (fr) Utilisation des polymeres procyanidoliques a titre d&#39;agents inhibuteurs des alpha-amylases et application dans des compositions a visees dietetiques
KR102043244B1 (ko) 수리취 추출물을 이용한 비만 개선용 및 항당뇨용 식품 조성물
KR102618848B1 (ko) 다시마 부산물 추출물의 가수분해물을 포함하는 면역 증강용 조성물
TW202245818A (zh) 可降低非酒精性脂肪肝之臺灣藜麥萃取物組合物及其用途
JP2006117566A (ja) 糖代謝改善剤
TWI580428B (zh) 一種以黑蒜頭及高粱酒糟製備預防動脈粥狀硬化之萃取物之方法及用途
Phachonpai et al. Exploring the efficacy of the wild mushroom Astraeus hygrometricus extract on lipid profiles, insulin resistance, and oxidative stress in rats fed a high-fat diet
WO2024133379A1 (fr) Procede de preparation d&#39;un extrait de cyanobacterie comprenant de la phycocyanine enrichie en oligoelements provenant de sources naturelles d&#39;oligoelements pour la fabrication de complements alimentaires
KR20230056234A (ko) 곤드레 추출물을 유효성분으로 함유하는 환경호르몬에 의한 대사 이상 개선 및 치료용 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131021

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

17Q First examination report despatched

Effective date: 20150526

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20170504